Verano Holdings (VRNO) Income from Non-Controlling Interests (2021 - 2023)
Verano Holdings (VRNO) posted quarterly Income from Non-Controlling Interests of -$78000.0 for Q4 2023, down 200.0% quarter-over-quarter from $78000.0 in Q3 2023.
Verano Holdings (VRNO) Income from Non-Controlling Interests (2021 - 2023) Analysis & Trends
Verano Holdings (VRNO) has reported Income from Non-Controlling Interests for 3 consecutive years, with -$78000.0 the latest figure, recorded in Q4 2023.
- In Q4 2023, Income from Non-Controlling Interests changed N/A year-over-year to -$78000.0; the TTM figure through Dec 2024 stood at -$78000.0 (changed N/A YoY), while the FY2022 annual figure was $291000.0, down 88.4% from the prior year.
- Income from Non-Controlling Interests declined to -$78000.0 in Q4 2023 per VRNO's latest filing, from $78000.0 in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at $594000.0 in Q4 2021 and bottomed at -$78000.0 in Q4 2023.
- Historically, Income from Non-Controlling Interests has averaged $255666.7 across 3 years, with a median of $194500.0 in 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 376,434.15 |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Verano Holdings | 433.71 Mn | 348.51 Mn | 99.70 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -78,000.00 |
| Sep 30, 2023 | 78,000.00 |
| Mar 31, 2022 | 291,000.00 |
| Dec 31, 2021 | 594,000.00 |
| Sep 30, 2021 | 551,000.00 |
| Jun 30, 2021 | 98,000.00 |